Wild, Damian

Somatostatin receptor antagonists for imaging and therapy.

Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 274

Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study

Antwi, K., Fani, M., Heye, T., Nicolas, G., Rottenburger, C., Kaul, F., Merkle, E., Zech, C. J., Boll, D., Vogt, D. R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging

Neuroendocrine Tumor Research AdvancesPancreatic function and diabetes

Cited by 124

Innovative imaging of insulinoma: the end of sampling? A review

Christ, E., Antwi, K., Fani, M., & Wild, D. (2020) · Endocrine-Related Cancer

Neuroendocrine Tumor Research AdvancesPancreatic function and diabetes

Cited by 78

Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.

Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 56

Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis

Friebe, L., Freitag, M. T., Braun, M., Nicolas, G., Bauman, A., Bushnell, D., Christ, E., & Wild, D. (2024) · Journal of Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 25